Tea and cancer prevention: Epidemiological studies

Jian Min Yuan, Canlan Sun, Lesley M. Butler

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Experimental studies have consistently shown the inhibitory activities of tea extracts on tumorigenesis in multiple model systems. Epidemiological studies, however, have produced inconclusive results in humans. A comprehensive review was conducted to assess the current knowledge on tea consumption and risk of cancers in humans. In general, consumption of black tea was not associated with lower risk of cancer. High intake of green tea was consistently associated with reduced risk of upper gastrointestinal tract cancers after sufficient control for confounders. Limited data support a protective effect of green tea on lung and hepatocellular carcinogenesis. Although observational studies do not support a beneficial role of tea intake on prostate cancer risk, phase II clinical trials have demonstrated an inhibitory effect of green tea extract against the progression of prostate pre-malignant lesions. Green tea may exert beneficial effects against mammary carcinogenesis in premenopausal women and recurrence of breast cancer. There is no sufficient evidence that supports a protective role of tea intake on the development of cancers of the colorectum, pancreas, urinary tract, glioma, lymphoma, and leukemia. Future prospective observational studies with biomarkers of exposure and phase III clinical trials are required to provide definitive evidence for the hypothesized beneficial effect of tea consumption on cancer formation in humans.

Original languageEnglish (US)
Pages (from-to)123-135
Number of pages13
JournalPharmacological Research
Volume64
Issue number2
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Tea
Epidemiologic Studies
Neoplasms
Carcinogenesis
Observational Studies
Phase III Clinical Trials
Phase II Clinical Trials
Upper Gastrointestinal Tract
Gastrointestinal Neoplasms
Urinary Tract
Pancreatic Neoplasms
Glioma
Prostate
Lymphoma
Prostatic Neoplasms
Leukemia
Breast
Biomarkers
Prospective Studies
Breast Neoplasms

Keywords

  • Black tea
  • Cancer prevention
  • Catechins
  • Epidemiology
  • Green tea
  • Polyphenols

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tea and cancer prevention : Epidemiological studies. / Yuan, Jian Min; Sun, Canlan; Butler, Lesley M.

In: Pharmacological Research, Vol. 64, No. 2, 08.2011, p. 123-135.

Research output: Contribution to journalArticle

Yuan, Jian Min ; Sun, Canlan ; Butler, Lesley M. / Tea and cancer prevention : Epidemiological studies. In: Pharmacological Research. 2011 ; Vol. 64, No. 2. pp. 123-135.
@article{6697ab2e50674ef2a3291737d27b0cf6,
title = "Tea and cancer prevention: Epidemiological studies",
abstract = "Experimental studies have consistently shown the inhibitory activities of tea extracts on tumorigenesis in multiple model systems. Epidemiological studies, however, have produced inconclusive results in humans. A comprehensive review was conducted to assess the current knowledge on tea consumption and risk of cancers in humans. In general, consumption of black tea was not associated with lower risk of cancer. High intake of green tea was consistently associated with reduced risk of upper gastrointestinal tract cancers after sufficient control for confounders. Limited data support a protective effect of green tea on lung and hepatocellular carcinogenesis. Although observational studies do not support a beneficial role of tea intake on prostate cancer risk, phase II clinical trials have demonstrated an inhibitory effect of green tea extract against the progression of prostate pre-malignant lesions. Green tea may exert beneficial effects against mammary carcinogenesis in premenopausal women and recurrence of breast cancer. There is no sufficient evidence that supports a protective role of tea intake on the development of cancers of the colorectum, pancreas, urinary tract, glioma, lymphoma, and leukemia. Future prospective observational studies with biomarkers of exposure and phase III clinical trials are required to provide definitive evidence for the hypothesized beneficial effect of tea consumption on cancer formation in humans.",
keywords = "Black tea, Cancer prevention, Catechins, Epidemiology, Green tea, Polyphenols",
author = "Yuan, {Jian Min} and Canlan Sun and Butler, {Lesley M.}",
year = "2011",
month = "8",
doi = "10.1016/j.phrs.2011.03.002",
language = "English (US)",
volume = "64",
pages = "123--135",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Tea and cancer prevention

T2 - Epidemiological studies

AU - Yuan, Jian Min

AU - Sun, Canlan

AU - Butler, Lesley M.

PY - 2011/8

Y1 - 2011/8

N2 - Experimental studies have consistently shown the inhibitory activities of tea extracts on tumorigenesis in multiple model systems. Epidemiological studies, however, have produced inconclusive results in humans. A comprehensive review was conducted to assess the current knowledge on tea consumption and risk of cancers in humans. In general, consumption of black tea was not associated with lower risk of cancer. High intake of green tea was consistently associated with reduced risk of upper gastrointestinal tract cancers after sufficient control for confounders. Limited data support a protective effect of green tea on lung and hepatocellular carcinogenesis. Although observational studies do not support a beneficial role of tea intake on prostate cancer risk, phase II clinical trials have demonstrated an inhibitory effect of green tea extract against the progression of prostate pre-malignant lesions. Green tea may exert beneficial effects against mammary carcinogenesis in premenopausal women and recurrence of breast cancer. There is no sufficient evidence that supports a protective role of tea intake on the development of cancers of the colorectum, pancreas, urinary tract, glioma, lymphoma, and leukemia. Future prospective observational studies with biomarkers of exposure and phase III clinical trials are required to provide definitive evidence for the hypothesized beneficial effect of tea consumption on cancer formation in humans.

AB - Experimental studies have consistently shown the inhibitory activities of tea extracts on tumorigenesis in multiple model systems. Epidemiological studies, however, have produced inconclusive results in humans. A comprehensive review was conducted to assess the current knowledge on tea consumption and risk of cancers in humans. In general, consumption of black tea was not associated with lower risk of cancer. High intake of green tea was consistently associated with reduced risk of upper gastrointestinal tract cancers after sufficient control for confounders. Limited data support a protective effect of green tea on lung and hepatocellular carcinogenesis. Although observational studies do not support a beneficial role of tea intake on prostate cancer risk, phase II clinical trials have demonstrated an inhibitory effect of green tea extract against the progression of prostate pre-malignant lesions. Green tea may exert beneficial effects against mammary carcinogenesis in premenopausal women and recurrence of breast cancer. There is no sufficient evidence that supports a protective role of tea intake on the development of cancers of the colorectum, pancreas, urinary tract, glioma, lymphoma, and leukemia. Future prospective observational studies with biomarkers of exposure and phase III clinical trials are required to provide definitive evidence for the hypothesized beneficial effect of tea consumption on cancer formation in humans.

KW - Black tea

KW - Cancer prevention

KW - Catechins

KW - Epidemiology

KW - Green tea

KW - Polyphenols

UR - http://www.scopus.com/inward/record.url?scp=79959560121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959560121&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2011.03.002

DO - 10.1016/j.phrs.2011.03.002

M3 - Article

C2 - 21419224

AN - SCOPUS:79959560121

VL - 64

SP - 123

EP - 135

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 2

ER -